BAF47 Stabilizing Compounds for Synovial Sarcoma Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for synovial sarcoma, including surgery, chemotherapy, and radiotherapy, do not effectively address the underlying mechanism of the disease, leading to high recurrence rates and limited disease-free survival rates, with no targeted biologics available.
Innovation Solution
Development of compounds that stabilize BAF47 within the SWI/SNF (BAF) complex, which are administered alone or in combination with existing anticancer agents like doxorubicin and ifosfamide, to treat or prevent synovial sarcomas.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If conventional chemotherapy (doxorubicin, ifosfamide) is used, then the number of remaining microscopic cancer cells is reduced, but the benefit for overall survival remains unclear and recurrence rates remain high
Solution Approach 1:
The patent extracts and targets the specific molecular mechanism driving synovial sarcoma (SS18-SSX fusion protein and BAF complex disruption) rather than using broad-spectrum chemotherapy. This selective approach addresses the root cause of the disease while sparing normal cells, potentially improving survival outcomes without the blunt force of conventional chemotherapy.
Solution Approach 2:
The patent introduces small molecule compounds as intermediaries that restore BAF47 stability and prevent its degradation by the SS18-SSX fusion protein. These compounds act as mediators between the pathological fusion protein and the BAF complex, reversing the molecular damage without requiring direct removal of the fusion protein.
2Reliability
If surgery is performed to remove the tumor, then curative outcomes are achieved in 20-70% of patients, but the disease is prone to early and late recurrences with ten-year disease-free survival rate of approximately 50%
Solution Approach 1:
The patent applies preliminary action by stabilizing BAF47 and restoring BAF complex function before or during tumor development. By preventing the molecular events that lead to synovial sarcoma progression, the treatment aims to eliminate the foundation for recurrence, extending disease-free survival beyond what surgery alone can achieve.
Solution Approach 2:
The patent changes the molecular parameters of the BAF complex by stabilizing BAF47 protein levels and preventing its degradation. This parameter change (restoring BAF47 stability) fundamentally alters the cellular environment to prevent tumor recurrence, addressing the limitation of surgery which removes the tumor but not the underlying molecular vulnerability.
3Adaptability or versatility
If no targeted biologics are developed, then treatment options remain limited to surgery, chemotherapy, and radiotherapy, but these approaches do not address the underlying mechanism of the disease
Solution Approach 1:
The patent replaces mechanical/physical treatment methods (surgery, radiotherapy) with a molecular-level chemical intervention. Small molecule compounds are used to specifically target and reverse the molecular defect (BAF47 degradation by SS18-SSX), substituting brute-force physical removal with precision molecular restoration.
Solution Approach 2:
The patent introduces small molecule compounds as intermediaries that specifically bind to and stabilize the BAF47-SS18-SSX interaction. These molecules act as mediators that restore normal BAF complex function without requiring removal of the fusion protein, providing a targeted biological response to a molecular pathology.
Data Source
AI summary
The present invention includes compound and methods that are useful in treating certain cancers, such as synovial sarcomas.